| 01 Juillet 2014
SUI results when the pelvic  floor muscles, which support the bladder and urethra, weaken to the  point that the muscles are not able to prevent urine from flowing when  pressure is placed on the abdomen, such as when the person laughs or  coughs. It occurs most often in women, due to childbirth and pregnancy. “Tissue engineering offers an  attractive method to regenerate sphincter muscle,” explained the study’s  corresponding author, Kirsi Kuismanen, from the department of  obstetrics and gynecology at Tampere University Hospital (TUH) in  Finland. She and her TUH colleagues teamed up with researchers from the  Adult Stem Cell Group of BioMediTech in Tampere and the University of  Twente in the Netherlands on the study. “Previously, various different  cell sources, such as skeletal muscle-derived stem cells (SkMSCs),  mesenchymal stem cells derived from bone marrow (BMSCs) and adipose stem  cells (ASCs), have been studied for treating urinary incontinence. The  SkMSCs and BMSCs would be a potential alternative for incontinence  therapy. However, when compared to ASCs, the major limitation of SkMSCs  and BMSCs is the difficulty to obtain these cells in large quantities,”  Dr. Kuismanen said. The study involved five SUI  patients who either did not want a sling implant or had undergone  implants but they proved unsuccessful. They were treated with ASCs  combined with bovine collagen gel, which is a bulking agent, and saline. Prior to the treatment, the  ASCs were isolated from subcutaneous fat and expanded for three weeks in  a laboratory. The mixture of ASCs and collagen was injected in the  patients who were followed for three, six and 12 months after the  injections. The primary end point was a cough test to measure the effect  of the treatment. Validated questionnaires were used to determine the  subjective cure rate. After six months, one out of  five patients displayed a negative cough test with full bladder. At one  year, the cough test was negative with three patients; two were  satisfied with the results and ended their treatment for SUI. Validated  questionnaires showed some subjective improvement in all five patients. “This is the first study  describing the use of autologous ASCs in combination with collagen gel  for female SUI treatments,” Dr. Kuismanen said. “Thus far, the treatment  with autologous ASCs has proven safe and well tolerated. However, the  feasibility and efficacy of the treatment were not optimal so additional  research is needed to develop SUI injection therapies.” “New treatments are needed for this common condition that affects millions of women,” said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.  “The current study, believed to be the first to evaluate adipose-derived  stem cells in combination with collagen, adds to the body of knowledge  about the safety and effectiveness of stem cell treatments for stress  urinary incontinence.” ### The full article, “Autologous  adipose stem cells in treatment of female stress urinary incontinence;  results of a pilot study,” can be accessed at http://www.stemcellstm.com.
Durham, NC – Medication and minimally invasive surgery to implant a sling can provide  relief for millions of people who suffer from stress urinary  incontinence (SUI), but not everyone responds to these therapeutic  methods. A new study in the current STEM CELLS Translational Medicine tests the safety and effectiveness of stem cells as an alternative SUI treatment.









